 Pacific Biosciences of California Inc NASDAQ: PACB reported Q3 sales of 34.9 million, beating the consensus of 33.23 million and up 83 YY. The company placed 44 Sequel II or IIe instruments in the quarter, bringing the total installed base to 326, compared to 168 a year ago. 